NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
Clinical Trials
15 trialsNCT06541262 2026-03-02
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Milton S. Hershey Medical Center
Phase 1/2 Recruiting
NCT06709495 2026-02-19
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT04901702 2026-02-09
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT01858168 2025-12-19
Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma
Massachusetts General Hospital
Phase 1 Completed
NCT05429502 2025-10-10
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
Novartis
Phase 1 Terminated
NCT04337177 2025-09-23
Flavored, Oral Irinotecan VAL-413 (OrotecanĀ®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Valent Technologies, LLC
Phase 1 Recruiting
NCT06023641 2025-08-19
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
St. Jude Children's Research Hospital
Phase 2 Recruiting
NCT06721689 2025-03-26
PEEL-224
Children's Hospital of Philadelphia
Phase 1/2 Recruiting
NCT03709680 2025-01-14
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Pfizer
Phase 2 Active not recruiting
NCT04625907 2024-05-23
FaR-RMS
University of Birmingham
Phase 1/2 Recruiting
NCT01355445 2019-09-18
VIT-0910
Centre Oscar Lambret
Phase 2 Completed
NCT02689336 2019-09-09
Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
Washington University School of Medicine
Phase 2 Withdrawn
NCT01055314 2017-08-29
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003718 2014-01-06
Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Unknown